Reading Time: 6 minutesAs the research team are starting to get stuck into planning our next International Symposium on ALS/MND we are taking a look back at some
Category: Treatments
Reading Time: 5 minutesThis is a guest blog written by Danielle Boyce, DPA, MPH, Executive Director, the Robert Packard Center for ALS Research and Answer ALS Research Program;
Reading Time: 4 minutesResearchers at King’s College London led by Professor Christopher Shaw, are the first in Europe to embark on a clinical trial targeting a specific genetic
Reading Time: 4 minutesThis is blog number 21 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 4 minutesThis is blog number 20 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 5 minutesThis is blog number 19 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 4 minutesThis is blog number 18 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 4 minutesThis is blog number 17 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 5 minutesThis is blog number 9 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green type correspond
Reading Time: 7 minutesGlobal biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in